Moleculin Biotech Net Income

Moleculin Biotech (MBRX) currently reports a net income of $-30M as of June 2026. That compares with $-27M in the prior-year period — down 14.2% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Moleculin Biotech's net income history and peer comparisons.

Moleculin Biotech's net income decreased from $-27M to $-30M — a 14.2% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Moleculin Biotech's net income of $-30M is lower than the Healthcare sector average of $16B. That is roughly 100.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Moleculin Biotech reported $-30M in net income as of June 2026. That compares with $-27M in the prior-year period — down 14.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-30M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Moleculin Biotech, and consider following MBRX for alerts when major investors trade the stock.